Paper5111993
Dopamine: release from the brain in vivo by amantadine.
Von Voigtlander PF and 1 other. Science, 1971. Cited by 96 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Dopamine: release from the brain in vivo by amantadine. Papers, record 5111993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5111993
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amantadine | Major topic |
| Brain | Major topic |
| Dopamine | Major topic |
| Animals | |
| Autoradiography | |
| Cats | |
| Caudate Nucleus | |
| Cerebral Ventricles | |
| Electric Stimulation | |
| Perfusion | |
| Tritium |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35,611,807 | Opening of the Diamondoid Cage upon Ionization Probed by Infrared Spectra of the Amantadine Cation Solvated by Ar, N2 , and H2 O. | Chemistry | 2022 | https://conductscience.org/library/papers/35611807 | PubMed |
| 33,624,170 | Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. | J Neural Transm (Vienna) | 2021 | https://conductscience.org/library/papers/33624170 | PubMed |
| 31,442,412 | Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. | Brain Res | 2019 | https://conductscience.org/library/papers/31442412 | PubMed |
| 29,898,194 | Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. | Braz J Psychiatry | 2018 | https://conductscience.org/library/papers/29898194 | PubMed |
| 29,695,911 | Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease. | Ther Clin Risk Manag | 2018 | https://conductscience.org/library/papers/29695911 | PubMed |
| 28,833,562 | Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). | Mov Disord | 2017 | https://conductscience.org/library/papers/28833562 | PubMed |
| 26,711,850 | Catecholaminergic based therapies for functional recovery after TBI. | Brain Res | 2016 | https://conductscience.org/library/papers/26711850 | PubMed |
| 24,497,943 | Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury. | PLoS One | 2014 | https://conductscience.org/library/papers/24497943 | PubMed |
| 22,308,176 | Targeting Dopamine in Acute Traumatic Brain Injury. | Open Drug Discov J | 2010 | https://conductscience.org/library/papers/22308176 | PubMed |
| 21,047,500 | Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats. | Brain Res | 2011 | https://conductscience.org/library/papers/21047500 | PubMed |
| 19,580,914 | Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. | Neurosci Biobehav Rev | 2009 | https://conductscience.org/library/papers/19580914 | PubMed |
| 17,522,851 | Specific features of sensorimotor cerebral cortex activity modulation by dopamine releaser amantadine. | Exp Brain Res | 2007 | https://conductscience.org/library/papers/17522851 | PubMed |
| 10,874,522 | Tremor-predominant Parkinson's disease. Approaches to treatment. | Drugs Aging | 2000 | https://conductscience.org/library/papers/10874522 | PubMed |
| 8,795,596 | Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. | J Neurol Neurosurg Psychiatry | 1996 | https://conductscience.org/library/papers/8795596 | PubMed |
| 8,741,085 | Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. | J Neurol | 1996 | https://conductscience.org/library/papers/8741085 | PubMed |
| 8,101,093 | Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. | J Neural Transm Gen Sect | 1993 | https://conductscience.org/library/papers/8101093 | PubMed |
| 6,435,991 | Anti-parkinsonian drugs today. | Drugs | 1984 | https://conductscience.org/library/papers/6435991 | PubMed |
| 6,215,256 | Amantadine modulates phencyclidine binding site sensitivity in rat brain. | Experientia | 1982 | https://conductscience.org/library/papers/6215256 | PubMed |
| 6,141,587 | Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants. | Psychopharmacology (Berl) | 1984 | https://conductscience.org/library/papers/6141587 | PubMed |
| 4,836,359 | [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)]. | Arch Psychiatr Nervenkr (1970) | 1974 | https://conductscience.org/library/papers/4836359 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5111993
GET https://conductscience.org/api/papers/v1/5111993/cited_by?page=2